Vadadustat + Darbepoetin alfa
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anemia
Conditions
Anemia
Trial Timeline
May 27, 2020 → Jun 22, 2022
NCT ID
NCT04313153About Vadadustat + Darbepoetin alfa
Vadadustat + Darbepoetin alfa is a phase 3 stage product being developed by Akebia Therapeutics for Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04313153. Target conditions include Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04313153 | Phase 3 | Completed |
| NCT03242967 | Phase 3 | Withdrawn |
| NCT02892149 | Phase 3 | Completed |
| NCT02865850 | Phase 3 | Completed |
| NCT02680574 | Phase 3 | Completed |
| NCT02648347 | Phase 3 | Completed |
Competing Products
20 competing products in Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aranesp® | Amgen | Approved | 84 |
| KER-047 | Keros Therapeutics | Phase 2 | 44 |
| LY2787106 | Eli Lilly | Phase 1 | 33 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| epoetin beta + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| recombinant human erythropoietin + recombinant human erythropoietin placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| recombinant human erythropoietin + recombinant human erythropoietin | Chugai Pharmaceutical | Phase 3 | 77 |
| darbepoetin alfa | Amgen | Phase 3 | 76 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 33 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| Alefacept | Astellas Pharma | Phase 1 | 33 |
| Roxadustat | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| Roxadustat | Astellas Pharma | Pre-clinical | 23 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |